The T α 1 peptide can be administered via subcutaneous injection or as a transdermal cream. T α 1 has been found to be very safe, and there have not been any documented side effects associated with its administration. It is approved in more than 37 countries for the treatment of hepatitis B, hepatitis C, and as an adjunct to chemotherapy and various vaccines.
For Growth Hormone (GH) to perform its anabolic (muscle building) affects it requires the presence of the body's most anabolic hormone: insulin. This is in contrast to GH related fat loss which requires insulin to be absent. However, since GHRP and fast-acting GHRH (Growth Hormone Releasing Hormone) products (i.e. Modified GRF 1-29) still need time to stimulate the body to release GH from the pituitary gland, the insulin spike must come after the injection and not before, otherwise the GH release will be blunted.
No growth hormone, or any supplement for that matter, is never going to equate to the same exact results for every user. So, what you experience, is not the same as the next user, and vice-versa. Further, the increase in results and how quickly you will see these results are going to differ for each user. So, make sure you understand this prior to start your dosage, to ensure you are not disappointed if you do not see each one of these benefits, on the very first day that you begin using the Ipamorelin. Also consider the fact that if you use it after food, or with a meal, results will improve. So, proper timing and proper diet and exercise regimen can greatly enhance the results you are going to realize when you are using Ipamorelin as well.
I have questions about combined therapy of CJC 1295 and Ipamorelin at the same time on a daily basis for both. The compounding pharmacies do not clearly state whether the CJC is with or without DAC. If it is the CJC with DAC, which sustains elevated GH and IGF-1 for several days, would taking it nightly in conjunction with the Ipramorelin, that is suggested to be taken TID but is being recommended only once at night, be over-stimulatory? If the CJC is without DAC, why take two pepetides simultaneously ,that have similar effects? I am just not clear why taking a daily dose of CJC with Ipamorelin as a single dose is better than taking the CJC with DAC twice per week alone or take the CJC with DAC for a while then switch to the Ipamorelin for a while?

Five patients in the study reported a serious AE; three in the AOD9604 20 mg group (basal cell carcinoma, moderate lipoma and squamous cell carcinoma), one in the 5 mg group (breast cancer) and one in the 10 mg group (malignant melanoma). According to the investigator, none of the SAEs reported were considered to be possibly, probably or definitely related to study medication (see discussion).

This is a great option for those who are looking to promote a steady and improved release of GH to get the benefits of increases in growth hormone and subsequently Insulin Like Growth Factor -1 (IGF-1) with almost no side effects. This therapy is effectively used for anti-aging purposes as well as those with inflammatory conditions, disease or those who have low IGF-1 levels.
There were concerns regarding the number of contraindications and precautions and whether consumers would be able to interpret these appropriately without a requirement for pharmacist advice. There were concerns regarding gastro-intestinal, renal and other adverse effects related to the potential interactions of ibuprofen and paracetamol. Also raised were concerns regarding the potential for paracetamol overdose.
It is well known that hGH is associated with increased IGF-1 levels. IGF-1 may have a variety of undesirable effects, including an increase in cancer risk [22, 23]. In the studies discussed herein, IGF-1 levels were monitored in all long-term studies but did not reveal clinically significant differences between dose groups or placebo. Therefore the 5 SAEs that occurred in the 12 week treatment study (three in the AOD9604 20 mg group (basal cell carcinoma, moderate lipoma and squamous cell carcinoma), one in the 10 mg group (malignant melanoma) and one in the 5 mg group (breast cancer)) could not be attributed to increased IGF-1 levels. The Principal Investigator considered none of the reported SAEs to be “possibly”, “probably” or “definitely related” to the study medication. The rationale behind this judgment was that none of the cancer forms occurred in the highest dosage group (30mg AOD9604/day), therefore a dose effect can be excluded. Further examination of the SAE cases indicated that these subjects had neglected their personal medical care for a longer period of time, so that the higher incidence of cancer may well have occurred due to the natural incidence rate of cancer events in the population.
Ipamorelin is very similar to the growth hormone releasing peptides (GHRPs) GHRP 2 and GHRP 6 in that it mimics ghrelin (the hunger hormone) and targets a specific HGH pulse. However, unlike other GHRPs, this peptide doesn’t affect the release of cortisol, acetylcholine, prolactin and aldosterone thereby minimizing side effects experienced with other GH therapies, such as increased hunger. Because there are virtually no negative side effects, Ipamorelin can be prescribed more aggressively and more frequently than other therapies without the risk of elevated cortisol and acetylcholine blood plasma levels. This helps optimize HGH levels for a longer period of time, leading to more successful health outcomes.
Amongst its metabolic effects, hGH can induce inhibition of lipoprotein lipase activity in adipose tissue, stimulating lipolysis in adipocytes, which results in the reduction of fat cell mass [4-7]. Moreover, a correlation has been found between adiposity and the reduced circulating levels of hGH [8]. When applied systemically, hGH reduces body fat mass and influences fat distribution [9]. Therefore, treatment with hGH should theoretically have a positive impact on obesity. However, long term treatment with hGH is associated with various health risks, including glucose intolerance and insulin resistance, diabetes, acromegaly, cancer, edema, and hypertension [10-13].
Overall, there were no AEs that were deemed to be “definitely related” to the study treatment. The percentage of AEs that were deemed to be “probably” or “possibly related” to study treatment was similar among all treatment groups including placebo. The most common classes of AE deemed to be “probably” or “possibly”related to study treatment were gastrointestinal disorders (5.2% overall) and nervous system disorders (4.9% overall).

CJC-1295 is also known by the names of Modified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC (DAC stands for Drug Affinity Complex) and also by its chemical name tetrasubstituted GRF (1-29). This variety of names makes it difficult for the average consumer to select or even research upon this compound. Since some manufacturers list all of its names and others list only one, it also becomes very confusing. However, there is a reason for this wide variety of names.
All our peptides are prescribed by experienced anti-ageing doctors, and arrive directly to you from the pharmacy. The prescription will include your name, product name, dose, and potency. The product arrives cold packed and reconstituted, ready to use. All of our peptides that are in injectable form also come with the syringes and swabs needed to complete your course.